HC Wainwright & Co. Downgrades Acelyrin to Neutral, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has downgraded Acelyrin (NASDAQ:SLRN) from Buy to Neutral and lowered the price target from $18 to $6.
August 15, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. has downgraded Acelyrin from Buy to Neutral and significantly lowered the price target from $18 to $6.
The downgrade from Buy to Neutral and the significant reduction in the price target from $18 to $6 by HC Wainwright & Co. is likely to negatively impact investor sentiment and the short-term stock price of Acelyrin.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100